Paper Details

  1. Home
  2. Paper Details

Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.

Author: , AronicaEleonora, BenovaBarbora, BorkowskaJulita, CuratoloPaolo, Domańska-PakiełaDorota, FeuchtMartha, Głowacka-WalasJagoda, HertzbergChristoph, HulshofHanna, JansenAnna C, JansenFloor, JóźwiakSergiusz, KotulskaKatarzyna, KrsekPavel, KwiatkowskiDavid J, LagaeLieven, MoaveroRomina, NabboutRima, RineyKate, SadowskiKrzysztof, SchollTheresa, SijkoKamil, WeschkeBernhard, WojdanKonrad, de RidderJessie

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Epilepsy develops in a majority of children with tuberous sclerosis complex (TSC) and is often resistant to medication. The EPISTOP clinical trial aimed to compare preventive versus conventional antiepileptic treatment in infants with TSC.
Paper Details　
Original Abstract of the Article :
Epilepsy develops in 70 to 90% of children with tuberous sclerosis complex (TSC) and is often resistant to medication. Recently, the concept of preventive antiepileptic treatment to modify the natural history of epilepsy has been proposed. EPISTOP was a clinical trial designed to compare preventive ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898885/

データ提供：米国国立医学図書館（NLM）

Preventing Epilepsy in Infants with Tuberous Sclerosis Complex: A New Hope for Early Intervention

Tuberous sclerosis complex (TSC), a rare genetic disorder, often leads to the development of epilepsy in affected children. This study explores the concept of preventive antiepileptic treatment to modify the natural history of epilepsy in infants with TSC. The EPISTOP trial, a groundbreaking clinical trial, aims to compare the effectiveness of preventive antiepileptic treatment with the conventional approach. The study is still ongoing but holds immense promise for preventing epilepsy in infants with TSC, potentially transforming their lives.

The Promise of Early Intervention for Epilepsy in TSC

This research represents a significant step towards early intervention for epilepsy in infants with TSC. The EPISTOP trial, with its focus on preventive antiepileptic treatment, holds the potential to change the course of epilepsy development in these children, improving their quality of life and long-term health outcomes.

Hope for Children with Tuberous Sclerosis Complex

This study offers a glimmer of hope for children with TSC, who often face significant challenges related to epilepsy. The potential for preventive treatment to modify the natural history of epilepsy in these infants is truly transformative, potentially leading to a brighter future for these children.

Dr. Camel's Conclusion

Imagine a vast desert, where a child with TSC encounters the unpredictable storms of epilepsy. The EPISTOP trial, like a sturdy camel caravan, aims to navigate these treacherous waters, protecting vulnerable children from the devastating effects of epilepsy through preventive intervention. This groundbreaking research offers a ray of hope for children with TSC, promising a future where they can thrive.

Date :
  1. Date Completed 2021-02-19
  2. Date Revised 2023-09-19
Further Info :

Pubmed ID

33180985

DOI: Digital Object Identifier

PMC7898885

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.